Picture Swiss Biotech Association Swiss Biotech Days 2025 SBD25 Basel 650x100px

Document › Details

Uniqure N.V.. (10/28/19). "Press Release: Uniqure Announces Third Quarter 2019 Results and Highlights Recent Company Progress". Lexington, MA & Amsterdam.

	Organisation	Uniqure N.V. (Nasdaq: QURE)
	Group	Uniqure (Group)
	Organisation 2	Bristol Myers Squibb (BMS) (Group)
	Product	etranacogene dezaparvovec (AMT-061)
	Product 2	AMT-130 (Huntington’s disease gene therapy, Uniqure)
	Person	Kapusta, Matthew (Matt) (Uniqure 201612– CEO before interim CEO before CFO before AngioDynamics + Smith & Nephew)
	Person 2	Cantor, Maria E. (Uniqure 201606– SVP IR + Communications before Ariad Pharmaceuticals + Genzyme)

Original document
accessed by [iito] on 2019-10-29

Record changed: 2023-06-05

Picture Swiss Biotech Association Swiss Biotech Days 2025 SBD25 Basel 650x200px

More documents for Uniqure (Group)

[1] Uniqure N.V.. (5/15/23). "Press Release: Uniqure Announces Sale of Royalty Interest in Hemgenix for up to $400 Million". Lexington, MA & Amsterdam....
[2] Uniqure N.V.. (1/31/23). "Press Release: uniQure and Apic Bio Enter into Global Licensing Agreement for APB-102, a Clinical Stage Gene Therapy for Patients with ALS Caused by Mutations in SOD1". Lexington, MA, Amsterdam & Cambridge, MA....
[3] Uniqure N.V.. (11/22/22). "Press Release: Uniqure Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B". Research Triangle Park, NC....
[4] Uniqure N.V.. (12/9/21). "Press Release: Uniqure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B". Lexington, MA, Amsterdam & King of Prussia, PA....
[5] Uniqure N.V.. (6/22/21). "Press Release: Uniqure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)". Lexington, MA, Amsterdam & Paris....
[6] Uniqure N.V.. (12/21/20). "Press Release: uniQure Announces Clinical Update on Hemophilia B Gene Therapy Program". Lexington, MA & Amsterdam....
[7] Uniqure N.V.. (6/24/20). "Press Release: Uniqure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy". Lexington, MA & Amsterdam....
[8] Uniqure N.V.. (6/17/20). "Press Release: Uniqure Announces the Appointment of Leonard E. Post, Ph.D. to Its Board of Directors". Lexington, MA & Amsterdam....
[9] Uniqure N.V.. (3/2/20). "Press Release: Uniqure Announces 2019 Financial Results and Highlights Recent Company Progress". Lexington, MA & Amsterdam....
[10] Uniqure N.V.. (3/2/20). "Press Release: Uniqure and Gen-X Enter into Research Collaboration and License Agreement for the Development of Novel Synthetic Promoters". Lexington, MA & Amsterdam....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]